This study aims to compare the diagnostic accuracy of Contrast-enhanced ultrasound (CEUS) for diagnosing hepatocellular carcinoma (HCC) with that of gadoxetic acid-enhanced liver magnetic resonance imaging (MRI) using non-invasive diagnostic criteria (American Association for the Study of Liver Disease (AASLD or Liver Imaging Reporting and Data System (LI-RADS) v2018 and Korean Liver Cancer Study Group- National Cancer Center Korea (KLCSG-NCC) v2018).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
117
CEUS is performed using SonoVue (Bracco, Milan, Italy) intravenous administration in eligible participants within a month before/after EOB-MRI.
EOB-MRI is performed using standard dose of hepatocyte specific contrast media (primovist or eovist) according to standard protocol of our institution.
Seoul National University Hospital
Seoul, South Korea
Diagnostic performance of CEUS for diagnosing HCC
accuracy, sensitivity, specificity of CEUS for HCC diagnosis
Time frame: 3 months after CEUS
Diagnostic performance of gadoxetic-acid liver MRI for diagnosing HCC using LI-RADSv2018
accuracy, sensitivity, specificity of MRI using LI-RADS v2018 for HCC diagnosis
Time frame: 3 months after MRI
Diagnostic performance of gadoxetic-acid liver MRI for diagnosing HCC using KLCSG-NCC guidelinev2018
accuracy, sensitivity, specificity of MRI using KLCSG-NCC guideline v2018 for HCC diagnosis
Time frame: 3 months after MRI
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.